SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.28 CNY | -0.69% |
|
-5.32% | -41.43% |
Projected Income Statement: Shenyang Xingqi Pharmaceutical Co.,Ltd.
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,468 | 2,117 | 2,680 | 3,082 |
| Change | - | - | - | 44.25% | 26.59% | 15% |
| EBITDA 1 | - | - | 361.4 | 976 | 1,312 | 1,606 |
| Change | - | - | - | 170.04% | 34.43% | 22.41% |
| EBIT 1 | - | - | 276.5 | 503 | 744 | 857 |
| Change | - | - | - | 81.9% | 47.91% | 15.19% |
| Interest Paid 1 | - | - | - | -1 | - | - |
| Earnings before Tax (EBT) 1 | - | - | 265 | 500 | 741 | 858 |
| Change | - | - | - | 88.68% | 48.2% | 15.79% |
| Net income 1 | 194.7 | 211.7 | 240 | 449 | 669 | 768 |
| Change | - | 8.72% | 13.39% | 87.06% | 49% | 14.8% |
| Announcement Date | 22-04-19 | 23-04-19 | 24-04-18 | - | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Shenyang Xingqi Pharmaceutical Co.,Ltd.
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Announcement Date | 22-04-19 | 23-04-19 | 24-04-18 | - | - | - |
Estimates
Cash Flow Forecast: Shenyang Xingqi Pharmaceutical Co.,Ltd.
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| CAPEX 1 | 261.9 | 204 | 452 | 599 |
| Change | - | -22.12% | 121.57% | 32.52% |
| Free Cash Flow (FCF) 1 | - | - | - | - |
| Change | - | - | - | - |
| Announcement Date | 24-04-18 | - | - | - |
1CNY in Million
Estimates
Forecast Financial Ratios: Shenyang Xingqi Pharmaceutical Co.,Ltd.
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
Profitability | ||||||
| EBITDA Margin (%) | - | - | 24.63% | 46.1% | 48.96% | 52.11% |
| EBIT Margin (%) | - | - | 18.84% | 23.76% | 27.76% | 27.81% |
| EBT Margin (%) | - | - | 18.06% | 23.62% | 27.65% | 27.84% |
| Net margin (%) | - | - | 16.36% | 21.21% | 24.96% | 24.92% |
| FCF margin (%) | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - |
Profitability | ||||||
| ROA | - | - | 12.61% | 17.7% | 20.6% | 18.8% |
| ROE | - | - | 14.77% | 21% | 23.8% | 21.5% |
Financial Health | ||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - |
Capital Intensity | ||||||
| CAPEX / Current Assets (%) | - | - | 17.85% | 9.64% | 16.87% | 19.44% |
| CAPEX / EBITDA (%) | - | - | 72.47% | 20.9% | 34.45% | 37.3% |
| CAPEX / FCF (%) | - | - | - | - | - | - |
Items per share | ||||||
| Cash flow per share 1 | - | - | 1.821 | 4.971 | 6.714 | 8.45 |
| Change | - | - | - | 173.06% | 35.06% | 25.85% |
| Dividend per Share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | 9.688 | 12.26 | 16.1 | 20.5 |
| Change | - | - | - | 26.59% | 31.28% | 27.33% |
| EPS 1 | 1.214 | 1.23 | 1.379 | 2.571 | 3.836 | 4.407 |
| Change | - | 1.26% | 12.12% | 86.53% | 49.17% | 14.9% |
| Nbr of stocks (in thousands) | 161,372 | 173,568 | 174,425 | 174,425 | 174,425 | 174,425 |
| Announcement Date | 22-04-19 | 23-04-19 | 24-04-18 | - | - | - |
1CNY
Estimates
| 2024 * | 2025 * | |
|---|---|---|
| P/E ratio | 29.7x | 19.9x |
| PBR | 6.22x | 4.74x |
| EV / Sales | 6.28x | 4.96x |
| Yield | - | - |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
76.28
Average target price
-
Annual profits - Rate of surprise
- Stock Market
- Equities
- 300573 Stock
- Financials Shenyang Xingqi Pharmaceutical Co.,Ltd.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition